Skip to Content

'
Cassian Yee, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
Department of Melanoma Medical Oncology
7455 Fannin
Unit Number: 904
Houston, TX 77054
Room Number: SCRB3.2026
Phone: 713-563-3750
Fax: 713-563-3424
Email: cyee@mdanderson.org

Education & Training

Degree-Granting Education

1986 University of Manitoba, Manitoba, Winnipeg, Canada, MD, Medicine

Postgraduate Training

1995-1998 Associate in Clinical Research, University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, WA
1994-1995 Research Associate, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
1991-1994 Research Fellowship, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
1989-1991 Clinical Residency, Internal Medicine, Stanford University Medical Center, Stanford, CA
1987-1989 Medical Research Council of Canada Fellow, Ontario Cancer Institute/ Princess Margaret Hospital, Toronto, Canada
1986-1987 General Comprehensive Internship, St. Michael's Hospital, Toronto, Canada

Board Certifications

2005 Medical Oncology (ABIM)

Experience/Service

Academic Appointments

Professor, Department of Medicine, Medical Oncology, University of Washington, Seattle, WA, 2010-2012
Member, Department of Immunology, Clinical Research Division Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 2009-2012
Associate Professor, Department of Medicine, Medical Oncology, University of Washington, Seattle, WA, 2004-2010
Associate Member, Immunology, Clinical Research Division Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 2003-2009
Assistant Professor, Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, 1999-2004
Assistant Member, Clinical Research Division Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 1998-2003

Other Appointments/Responsibilities

Affiliate Member, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 2009-1/2013
Active Staff, Swedish Medical Center, Seattle, WA, 2000-present
Active Staff, Seattle Cancer Care Alliance, Seattle, WA, 1999-present

Honors and Awards

2009 Elected to American Society for Clinical Investigation
2006-2012 Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund
2001-2006 Damon Runyon-Lilly Foundation, Clinical Investigator Award, Damon Runyon-Lilly Foundation
2000-2004 Cancer Research Institute Investgator Award, Cancer Research Institute
1995-2000 Burroughs Wellcome Fund Career Award in Biomedical Sciences, Burroughs Wellcome Fund
1994-1997 National Cancer Institute of Canada Fellowship, National Cancer Institute of Canada
1991 Stanford University Housestaff Research Award, Stanford University
1987-1989 Medical Research Council of Canada Post-MD Fellowship, Medical Research Council of Canada
1983-1985 Terry Fox Cancer Research Scholarship (NCI of Canada, Terry Fox Cancer Research

Professional Memberships

American Association of Cancer Research
Member, 2012
American Association of Immunologist (AAI)
Block Symposium Abstract Programming Co-Chair for Tumor Immunotherapy, 2008-present
American Association of Immunologists
Member, 2012
American Society for Clinical Investigations
Member, 2012
American Society of Clinical Oncology
Member, 2012
Fred Hutchinson Cancer Research Center, Seattle, WA
Committee Member - Solid Tumor Candidate Search Committee, Clinical Research Division, 2005-present
Institutional Biosafety Committee member (SCCA
Member, 2001-present
International Society for Biological Therapy of Cancer
member, 2012
National Institute of Health (NIH)
CII Study Section Member, 2012-2016
Ontario Institute of Cancer Research External Advisory Board
Member, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Yee C. Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res 19(17):4550-2, 9/1/2013. e-Pub 8/6/2013. PMID: 23922301.
2. Park G, Chung HJ, Kim K, Lim SA, Kim J, Kim YS, Liu Y, Yeo WH, Kim RH, Kim SS, Kim JS, Jung YH, Kim TI, Yee C, Rogers JA, Lee KM. Immunologic and Tissue Biocompatibility of Flexible/Stretchable Electronics and Optoelectronics. Adv Healthc Mater. e-Pub 9/1/2013. PMID: 23996980.
3. Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol 191(4):1567-77, 8/15/2013. e-Pub 7/12/2013. PMCID: PMC3732835.
4. Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KM. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res 73(8):2598-607, 4/2013. e-Pub 4/2013. PMID: 23580577.
5. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD (co-corresponding athors: CY and PDG). Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5(174):174ra27, 2/2013. PMCID: PMC3678970.
6. Jun, SH;Kim, K;An, HJ; Kim, BC; Sonn, CH; Kim, M; Doh, J;Yee, C;Lee, KM;Kim, J. Ethanol-Dispersed Polymer Nanofibers as a Highly Selective Cell Isolation and Release Platform for CD4(+) T Lymphocytes. Advanced Functional Materials 22(21):4448-4455, 11/2012.
7. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118(18):4564-70, 9/15/2012. e-Pub 2/22/2012. PMCID: PMC3361576.
8. Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KM. Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett 12(8):4018-24, 8/8/2012. e-Pub 7/26/2012. PMID: 22784189.
9. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 109(12):4592-7, 3/2012. e-Pub 3/2012. PMCID: PMC3311364.
10. Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 35(2):131-41, Feb-Mar, 2/2012. PMCID: PMC3288118.
11. Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson C, Nepom G, Yee C, Cerosaletti K. Ultra-sensitive detection of rare T cell clones. J Immunol Methods 375(1-2):14-9, 1/31/2012. e-Pub 9/10/2011. PMID: 21945395.
12. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7(2):e32165, 2012. e-Pub 2/27/2012. PMCID: PMC3288075.
13. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem P. Merkel cell polyomavirus-specific CD8 and CD4 T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17(21):6671-80, 11/1/2011. e-Pub 9/9/2011. PMCID: PMC3207011.
14. Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita M. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther 18(8):827-34, 8/2011. e-Pub 3/10/2011. PMID: 21390072.
15. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17(7):1664-73, 4/1/2011. e-Pub 2/15/2011. PMID: 21325070.
16. Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh V. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 185(10):5732-42, 11/15/2010. e-Pub 10/6/2010. PMCID: PMC3044081.
17. Abdul-Alim CS, Li Y, Yee C. Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol 184(11):6514-21, 6/1/2010. e-Pub 5/7/2010. PMCID: PMC3313650.
18. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4(3):e4749, 2009. e-Pub 3/9/2009. PMCID: PMC2650617.
19. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358(25):2698-703, 6/19/2008. PMCID: PMC3277288.
20. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1):229-35, 1/2008. e-Pub 10/2007. PMCID: PMC2200808.

Editorials

1. Yee C, De Vita VT, Lawrence TS, Rosenberg SA. Adoptive therapy using antigen-specific T-cell clones. Cancer J(16(4)):367-73, 1/2010.

Book Chapters

1. Pollack S & Yee C. Adoptive T Cell Therapy of Solid Tumor Malignancies. In: Innate and adaptive. immune regulation and Cancer immunotherapy. Wang, RF Ed. Springer Press, 2011.
2. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. In: Sarcoma. 2011, 438940, e-Book 2011. PMCID: PMC3034923.
3. Yee C. Tumor Immunotherapy. In: The Molecular Biology of Cancer, 2. Ed(s) Spelengaris S. Blackwell Publishing: Malden MA, 2011.
4. Yee C. Adoptive therapy using antigen-specific T-cell clones. In: Cancer J. 16, 4, 367-73, 7/2010. ISBN: 20693849.

Grant & Contract Support

Title: Gastric Cancer Immunity and Immunotherapy
Funding Source: Sister Institution Network Funding (MDACC)
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2014
 
Title: Adoptive T Cell Therapy for Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 6/1/2013 - 5/31/2018
 
Title: Roswell Park Cancer Institute Ovarian Cancer SPORE
Funding Source: NIH/NCI
Role: Co-PI, Project 2
Duration: 4/1/2013 - 3/31/2018
 
Title: Adoptive Cellular Therapy: Strategies to Enhance Safety, Persistence and Efficacy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2013 - 3/31/2018
 
Title: Adoptive Cell Transfer for Cancer Treatment
Funding Source: Stand Up to Cancer - Cancer Research Institute
Role: Co-Principal Investigator
Duration: 1/1/2013 - 12/31/2015
 
Title: Targeting MCPyV to Overcome Immune Evarsion in Merkel Cell Carcinoma
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Nghiem
Duration: 9/30/2011 - 8/31/2016
 
Title: Adoptive CD4 T Cell Therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2011 - 3/31/2016
 
Title: Targeting Cancer-Testis Antigens in Sarcoma
Funding Source: Gilman Foundation
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2014
 
Title: Strategies to Enhance the Efficacy of Adoptive T Cell Therapy
Funding Source: MRA
Role: Principal Investigator
Duration: 8/1/2010 - 8/31/2014
 
Title: Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/9/2010 - 1/31/2015
 
Title: Potentiating Adoptive T Cell Therapy by Immunomodulation - now in NCE
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2009 - 4/29/2011
 
Title: The use of IL-21 modulated CTL for Adoptive T Cell Therapy
Funding Source: Harry LLoyd CTR
Role: Principal Investigator
Duration: 6/1/2009 - 5/31/2011
 
Title: Phase I/II study of cellular adoptive immunotheraphy using autologous CD8+NY-1 specific t Cell clones and anti-CTLA-4 for patients with metastatic melanoma.
Funding Source: CRI
Role: Co-Principal Investigator
Principal Investigator: Greenberg
Duration: 2/1/2009 - 1/31/2012
 
Title: Cancer Center Support Grant
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Corey, L
Duration: 1/1/2009 - 12/31/2011
 
Title: Identification of T-Cell defined Antigens in Ovarian Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/22/2008 - 8/31/2011
 
Title: Adoptive Therapy of Cancer: Strategies to Augment the Antigen-Specific T-Cell Response
Funding Source: Burroughs Wellcome Fund
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2012
 
Title: Wnt Modulators and Tumor Antigen Expression of Human Melanoma Cells
Funding Source: CCSG Pilot Award
Role: Principal Investigator
 
Title: Adoptive T Cell Therapy Following CD25 Lymphodepletion
Funding Source: NIH/NCI
Role: Principal Investigator

Last updated: 10/9/2013